Nuclear medicine company NorthStar Medical Radioisotopes announced that it has successfully produced molybdenum-99 at its recently completed accelerator production facility at its Beloit, Wis., campus. According to NorthStar, the event marks a major milestone in advancing the company’s proprietary electron accelerator technology for the non-uranium–based production of the critical medical radioisotope.

BWXT Medical has submitted a new drug application to the U.S. Food and Drug Administration to request approval of its technetium-99m generator for medical imaging. A daughter isotope of molybdenum-99, Tc-99m is used in more than 40 million diagnostic procedures annually. BWXT Medical is a subsidiary of Lynchburg, Va.-based BWX Technologies.